Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Purinomia Biotech is raising $1,999,998.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Anderson Wang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Purinomia Biotech

Targeting purinergic signaling. Biologicals and small molecule development to target key ectonucleotidases for treatment of cancer, autoimmunity, inflammatory disease and metabolic syndrome. The company develops therapies and treatments based on small molecule compounds manufactured through chemical synthesis to target key ectonucleotidases and purinergic signaling.

To learn more about Purinomia Biotech, visit http://purinomia.com/

Contact:
Anderson Wang, Chief Financial Officer
781-874-0926
anderson@purinomia.com
https://www.linkedin.com/in/anderson-z-wang-2633ab8b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved